| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ESP Stock Overview
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.
Esperite Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.022 |
| 52 Week High | €0.038 |
| 52 Week Low | €0.015 |
| Beta | 0 |
| 1 Month Change | 5.71% |
| 3 Month Change | -9.02% |
| 1 Year Change | -33.13% |
| 3 Year Change | -66.36% |
| 5 Year Change | -95.63% |
| Change since IPO | -99.67% |
Recent News & Updates
Shareholder Returns
| ESP | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | 11.0% | 0.2% | -0.6% |
| 1Y | -33.1% | -15.3% | -14.5% |
Return vs Industry: ESP underperformed the Dutch Biotechs industry which returned -15.3% over the past year.
Return vs Market: ESP underperformed the Dutch Market which returned -14.5% over the past year.
Price Volatility
| ESP volatility | |
|---|---|
| ESP Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NL Market | 8.1% |
| 10% least volatile stocks in NL Market | 3.1% |
Stable Share Price: ESP is more volatile than 90% of Dutch stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ESP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Frédéric Amar | https://www.esperite.com |
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord.
Esperite Fundamentals Summary
| ESP fundamental statistics | |
|---|---|
| Market Cap | €1.16m |
| Earnings (TTM) | -€18.72m |
| Revenue (TTM) | €13.57m |
0.0x
P/S Ratio0.0x
P/E RatioIs ESP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESP income statement (TTM) | |
|---|---|
| Revenue | €13.57m |
| Cost of Revenue | €4.50m |
| Gross Profit | €9.07m |
| Other Expenses | €27.78m |
| Earnings | -€18.72m |
Last Reported Earnings
Jun 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ESP perform over the long term?
See historical performance and comparisonValuation
Is ESP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ESP?
Other financial metrics that can be useful for relative valuation.
| What is ESP's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €1.16m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ESP's PB Ratio compare to its peers?
| ESP PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.7x | ||
VVY Vivoryon Therapeutics | 11.1x | 71.8% | €183.0m |
PHARM Pharming Group | 3x | 33.4% | €585.9m |
HXL Hexima | 0.2x | 58.1% | AU$2.0m |
RHOVAC RhoVac | 0.5x | n/a | kr15.2m |
ESP Esperite | n/a | n/a | €1.2m |
Price-To-Book vs Peers: Insufficient data to calculate ESP's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Earnings Ratio vs Industry
How does ESP's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Book vs Industry: Insufficient data to calculate ESP's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is ESP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ESP's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ESP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ESP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ESP's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Take a look at our analysis of ESP's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Esperite regulatory filings.
Future Growth
How is Esperite forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
42.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Esperite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of ESP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Esperite competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Esperite performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
21.4%
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Esperite has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Discover strong past performing companies
- When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Esperite's management and board experience and expertise to assess their ability to deliver on their strategic promises.
Financial Health
How is Esperite's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
In this section we usually analyse Esperite's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Esperite has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
Discover healthy companies
- Take a look at our analysis of ESP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Esperite's cash and debt levels may be found in its annual reports archived here.
- Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Esperite's financial data was last updated here.
Dividend
What is Esperite current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ESP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: ESP is not paying a notable dividend for the Dutch market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ESP has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
8.6yrs
Average board tenure
CEO
Frédéric Amar (58 yo)
8.42yrs
Tenure
€510,000
Compensation
Mr. Frédéric A. Amar has been Chief Executive Officer and Executive Director of Esperite N.V. (Formerly Cryo-Save Group N.V.) since March 19, 2014 and served as its Non Executive Director since November 20...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Frédéric's total compensation is reasonable compared to companies of similar size in the Dutch market.
Compensation vs Earnings: Insufficient data to compare Frédéric's compensation with company performance.
Board Members
Experienced Board: ESP's board of directors are considered experienced (8.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Esperite N.V.'s employee growth, exchange listings and data sources
Key Information
- Name: Esperite N.V.
- Ticker: ESP
- Exchange: ENXTAM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €1.162m
- Shares outstanding: 52.33m
- Website: https://www.esperite.com
Number of Employees
Location
- Esperite N.V.
- Herengracht 282
- Amsterdam
- Noord-Holland
- 1016 BX
- Netherlands
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/07 00:00 |
| End of Day Share Price | 2022/08/05 00:00 |
| Earnings | 2018/06/30 |
| Annual Earnings | 2017/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.